Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Treatment of acute exacerbations of multiple sclerosis in adults

Michael J Olek, DO
Section Editor
Francisco González-Scarano, MD
Deputy Editor
John F Dashe, MD, PhD


Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the central nervous system that is a leading cause of disability in young adults.

Despite dramatic advances in the clinical assessment of MS due to the widespread availability of brain and spine MRI, our understanding of the basic etiology of the disease remains limited. Full control of the disease and the repair of damaged myelin are key objectives for current and future investigators.

The treatment of acute exacerbations of MS is reviewed here. Other aspects of MS treatment are discussed separately. (See "Disease-modifying treatment of relapsing-remitting multiple sclerosis in adults" and "Treatment of progressive multiple sclerosis in adults" and "Symptom management of multiple sclerosis in adults".)


Indications for treatment of an acute exacerbation (relapse) in patients with MS include functionally disabling symptoms with objective evidence of neurologic impairment such as loss of vision, motor, and/or cerebellar symptoms. Mild sensory attacks are often not treated in the same manner, although symptomatic relief is sometimes necessary because of patient discomfort (eg, due to paresthesia).

Patients with relapsing-remitting MS who manifest current disease activity by either clinical symptoms or recent MRI lesions should be offered treatment with disease-modifying therapy. This is discussed separately. (See "Disease-modifying treatment of relapsing-remitting multiple sclerosis in adults", section on 'Starting disease-modifying therapy'.)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Tue Oct 06 00:00:00 GMT+00:00 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Galea I, Ward-Abel N, Heesen C. Relapse in multiple sclerosis. BMJ 2015; 350:h1765.
  2. Kupersmith MJ, Kaufman D, Paty DW, et al. Megadose corticosteroids in multiple sclerosis. Neurology 1994; 44:1.
  3. Murray TJ. Diagnosis and treatment of multiple sclerosis. BMJ 2006; 332:525.
  4. Filippini G, Brusaferri F, Sibley WA, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000; :CD001331.
  5. Burton JM, O'Connor PW, Hohol M, Beyene J. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev 2012; 12:CD006921.
  6. Le Page E, Veillard D, Laplaud DA, et al. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet 2015; 386:974.
  7. Barnes D, Hughes RA, Morris RW, et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997; 349:902.
  8. Martinelli V, Rocca MA, Annovazzi P, et al. A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS. Neurology 2009; 73:1842.
  9. Morrow SA, Stoian CA, Dmitrovic J, et al. The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology 2004; 63:1079.
  10. Thompson AJ, Kennard C, Swash M, et al. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology 1989; 39:969.
  11. Brod SA, Morales MM. Bio-equivalence of IM and SQ H.P. Acthar Gel. Biomed Pharmacother 2009; 63:251.
  12. Morrow SA, Barr J, Rosehart H, Ulch S. Depression and hypomania symptoms are associated with high dose corticosteroids treatment for MS relapses. J Affect Disord 2015; 187:142.
  13. Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46:878.
  14. Weiner HL, Dau PC, Khatri BO, et al. Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology 1989; 39:1143.
  15. Cortese I, Chaudhry V, So YT, et al. Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011; 76:294.
  16. Keegan M, König F, McClelland R, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005; 366:579.